We are live on ! Find out more
RPID icon

Rapid Micro Biosystems

59 hedge funds and large institutions have $181M invested in Rapid Micro Biosystems in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 13

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

11.01% more ownership

Funds ownership: 62.22%73.23% (+11%)

7% more funds holding

Funds holding: 5559 (+4)

21% less capital invested

Capital invested by funds: $228M → $181M (-$46.9M)

Holders
59
Holders Change
+4
Holders Change %
+7.27%
% of All Funds
0.93%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
13
Increased
22
Reduced
13
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$57.3M
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$23.4M +$9.19M +1,247,440 +57%
DCP
3
D1 Capital Partners
New York
$18M
KLM
4
Kennedy Lewis Management
New York
$12.7M +$11.1M +1,506,262 +419%
JP Morgan Chase
5
JP Morgan Chase
New York
$11.1M -$1.07M -145,170 -8%
BlackRock
6
BlackRock
New York
$11.1M +$1.8M +245,098 +18%
AWGLSCP
7
ABG-WTT Global Life Science Capital Partners
Hong Kong
$7.05M +$7.65M +1,038,296 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$6.5M +$4.11M +558,028 +140%
Adage Capital Partners
9
Adage Capital Partners
Massachusetts
$4.75M +$875K +118,757 +20%
ABG
10
Ally Bridge Group
New York
$4.75M +$1.93M +261,704 +60%
GCM
11
Glenview Capital Management
New York
$4.52M +$4.9M +665,807 New
AI
12
Advent International
Massachusetts
$3.92M
State Street
13
State Street
Massachusetts
$2.86M +$475K +64,462 +18%
RPAM
14
Rhenman & Partners Asset Management
Sweden
$2.04M +$765K +103,913 +53%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.54M +$601K +81,641 +56%
PA
16
Perceptive Advisors
New York
$1.29M -$1.44M -194,948 -51%
TD Asset Management
17
TD Asset Management
Ontario, Canada
$909K +$374K +50,740 +61%
WP
18
Woodline Partners
California
$887K -$817K -110,908 -46%
Northern Trust
19
Northern Trust
Illinois
$886K +$366K +49,725 +62%
FAM
20
Fred Alger Management
New York
$858K -$5.25K -713 -0.6%
Jacobs Levy Equity Management
21
Jacobs Levy Equity Management
New Jersey
$639K +$693K +94,173 New
Bank of New York Mellon
22
Bank of New York Mellon
New York
$429K +$328K +44,482 +238%
Manulife (Manufacturers Life Insurance)
23
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$366K +$389K +52,875 New
Ameriprise
24
Ameriprise
Minnesota
$347K +$2.65K +360 +0.7%
TGA
25
TPG GP A
Texas
$325K

RPID Hedge Fund Activity: Q1 2022 in Review

59 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Rapid Micro Biosystems (RPID) for Q1 2022, worth a combined $181M — down 21% from $228M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new RPID positions and 9 closed out — a net gain of 4 holders — while 22 added to existing stakes and 13 trimmed.

The largest buyer was Kennedy Lewis Management, adding an estimated $11.1M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $2.95M sold.

  • 59 institutional investors held Rapid Micro Biosystems (RPID) as of Q1 2022, up from 55 in Q4 2021.
  • Funds reported $181M of Rapid Micro Biosystems stock for Q1 2022, down 21% quarter-over-quarter.
  • 13 funds opened new Rapid Micro Biosystems positions in Q1 2022 and 9 closed out, a net change of +4 holders.
  • The largest Rapid Micro Biosystems buyer in Q1 2022 was Kennedy Lewis Management, an estimated $11.1M added.
  • The largest Rapid Micro Biosystems seller in Q1 2022 was Pura Vida Investments, an estimated $2.95M sold.

Based on aggregated 13F filings for Q1 2022.